【摘要】：目的系統(tǒng)評(píng)價(jià)尼妥珠單抗治療食管癌的有效性和安全性。方法檢索Medline、EMbase、Cochrane Library、Clinical Trials、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)、相關(guān)期刊論文、維普和萬(wàn)方數(shù)據(jù)庫(kù),收集尼妥珠單抗治療食管癌的臨床試驗(yàn),試驗(yàn)組予以尼妥珠單抗聯(lián)合常規(guī)放化療/化療方案治療,對(duì)照組予以常規(guī)放化療/化療方案治療。用Rev Man 5.3對(duì)有效率、控制率、生存率和藥物不良反應(yīng)發(fā)生率等主要指標(biāo)進(jìn)行Meta分析。結(jié)果共納入10項(xiàng)研究,共計(jì)535例患者。試驗(yàn)組和對(duì)照組的有效率分別為79.84%和65.96%;1年生存率分別為83.76%和67.13%;3年生存率分別為30.00%和14.29%;1年無(wú)進(jìn)展生存率分別為85.26%和69.47%,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。試驗(yàn)組和對(duì)照組的控制率分別為90.71%和79.88%;血液學(xué)毒性發(fā)生率分別為52.17%和50.95%;胃腸道反應(yīng)發(fā)生率分別為31.90%和38.79%;放射性食管炎發(fā)生率分別為41.15%和36.17%;放射性肺炎發(fā)生率分別為15.82%和19.02%,差異均無(wú)統(tǒng)計(jì)學(xué)意義(均P0.05)。結(jié)論尼妥珠單抗對(duì)提高食管癌患者有效率并延長(zhǎng)生存期有優(yōu)勢(shì),且未增加藥物不良反應(yīng)的發(fā)生,可推薦聯(lián)合放化療/放療用于食管癌患者治療。
[Abstract]:Objective to evaluate the efficacy and safety of neytozumab in the treatment of esophageal carcinoma. Methods Medline,EMbase,Cochrane Library,Clinical Trials, Chinese Biomedical Literature Database, Chinese Journal Full-text Database, Weip and Wanfang databases were searched, and the clinical trials of Niytozumab in the treatment of esophageal carcinoma were collected. The experimental group was treated with niytozumab combined with conventional radiotherapy and chemotherapy, while the control group was treated with routine chemotherapy / radiotherapy. The effective rate, control rate, survival rate and incidence rate of adverse drug reactions were analyzed by Meta with Rev Man 5.3. Results A total of 535 patients were included in 10 studies. The effective rates of the two groups were 79.84% and 65.96%, the 1-year survival rates were 83.76% and 67.13%, the 3-year survival rates were 30.00% and 14.29%, respectively. The 1 year progression-free survival rate was 85.26% and 69.47%, respectively, and the difference was statistically significant (P0.05). The control rates of the test group and the control group were 90.71% and 79.88%, the incidence of hematological toxicity were 52.17% and 50.955%, the incidence of gastrointestinal reaction were 31.90% and 38.79%, respectively. The incidence of radiation esophagitis was 41.15% and 36.17%, and the incidence of radiation pneumonia was 15.82% and 19.02%, respectively. The difference was not significant (P0.05). Conclusion Niytozumab has advantages in improving the effective rate and prolonging the survival time of esophageal cancer patients, and does not increase the incidence of adverse drug reactions. It is recommended that combined radiotherapy and chemotherapy / radiotherapy should be used in the treatment of esophageal cancer patients.
【作者單位】： 首都醫(yī)科大學(xué)附屬北京世紀(jì)壇醫(yī)院藥劑科;北京大學(xué)藥學(xué)院藥事管理與臨床藥學(xué)系;
【分類號(hào)】：R735.1

【相似文獻(xiàn)】

相關(guān)期刊論文 前5條

1 譚永才;程濤;;碘(~(131)I)美妥昔單抗治療AFP升高1例[J];廣東醫(yī)學(xué);2009年10期

2 劉玉琳;王軍;;細(xì)胞免疫在單抗治療腫瘤中的作用研究進(jìn)展[J];現(xiàn)代免疫學(xué);2011年01期

3 阮新建;王飛;宋飛翔;賈得前;;貝伐珠單抗治療惡性腫瘤的相關(guān)不良反應(yīng)及處理[J];中國(guó)醫(yī)藥導(dǎo)刊;2013年11期

4 倪鳳明;姜新;馬利新;黃祥;侯威;陳祥;曲雅勤;;放療聯(lián)合尼妥珠單抗治療晚期復(fù)發(fā)直腸癌的療效[J];中國(guó)老年學(xué)雜志;2014年07期

5 ;[J];;年期

相關(guān)重要報(bào)紙文章 前1條

1 美國(guó)食品藥品管理局 歐盟藥品管理局網(wǎng)站;貝伐珠單抗治療乳腺癌風(fēng)險(xiǎn)評(píng)價(jià)研究引發(fā)廣泛關(guān)注[N];中國(guó)醫(yī)藥報(bào);2011年

，

本文編號(hào)：2395082